Organisational change, health economics and evaluation
Hypothesis: Evidence about the efficacy, weaknesses and cost-effectiveness of introduced interventions is required to enable relevant actors in the health system to make better decisions about policy at an organisational, practitioner or patient level.
HCAI and AMR are a source of substantial health and economic burden in NHS England and OECD countries – an increasing burden due to, inter alia, increasingly complex morbidities managed in hospitals, injudicious use of antimicrobial agents, problems with adherence to antimicrobial medication in the community and healthcare institutions, sub-standard infection prevention and control in healthcare institutions, lack of new diagnostics and chemotherapeutic agents, and sub-optimal uptake of cost-effective interventions even when these are recommended as national or institutional policies.
Yet, few studies have estimated health and economic burden of HCAI and AMR. In order to address evidence gaps, and to develop evidence-based policies, we have established a multidisciplinary group of leading experts and scholars in health systems, health economics, public health, epidemiology, communicable disease control, organisational behaviour, management and clinical medicine, who bring a wealth of experience in qualitative, quantitative and mixed-methods of inquiry, translational and implementation research and modelling.
2 column general content block - Organisational change
Professor Rifat Atun
Visiting Professor at Imperial College London and Professor of Global Health Systems at Harvard University. Professor Atun’s research explores how contextual and health systems factors influence the adoption and diffusion of new technologies (e.g. diagnostics) and complex health innovations (e.g. disease control programmes for TB, HIV, HCAI, or malaria). His research also focuses on health and the economic impact of disease management programmes or health-care innovations.
Doctor Julie Robotham
Senior mathematical modeller/health economist, Public Health England. Julie’s expertise is in conducting mathematical modelling to assess effectiveness and cost-effectiveness of infectious disease interventions, with particular interest in modelling HCAI and AMR and subsequent evaluation of infection prevention and control.